China’s Mass COVID Testing Helps Elite Groups Get Rich, While Depleting Medical Insurance Funds

Indo-Pacific Conflict Zone
34 followers
8 Video Views·Aug 30, 2022
Since the beginning of this year, after seemingly endless rounds of virus outbreaks, China’s cities have adopted routine nucleic acid testing for residents as a pandemic control measure.
Who benefits financially from China's massive COVID testing?
Is the public caught in a scheme to line the elite's pockets?
If so, what's being done about it?
Stick around to find out.
China's mass COVID testing helps the elite get rich
while the medical insurance funds are sucked dry.
Since the beginning of this year,
after seemingly endless rounds of virus outbreaks,
China's cities have adopted routine nucleic acid testing
for residents as a pandemic control measure.
The Chinese authorities are marketing this large-scale testing,
provided free of charge,
as a shining example of upright leadership.
While the CCP authorities parrot their concern
for the health of the Chinese public,
the state medical insurance fund coffers are emptied
to line the pockets of China's most elite public interest groups.
The battle between local governments and the medical insurance funds.
China's National Medical Insurance Administration
and three other government agencies jointly issued
a notice recently announcing
that they would investigate how medical insurance funds
have been used in the past two and a half years.
In addition to a routine inspection checklist,
the administration will focus on inappropriate charges
for nucleic acid or antigen tests used to screen for COVID-19.
At the same time,
the National Medical Insurance Administration
notified local governments
that the cost of mass COVID-19 testing
is a burden not to be carried
by the public's medical insurance funds.
Needless to say,
many local governments have been covering the cost of mass testing
with the public's medical insurance funds
since the beginning of the pandemic.
The research team of Huaqiang Securities
looked into relevant regulations in Shenzhen,
Qingdao,
Shouxian,
and other cities
where nucleic acid testing is the norm.
The team concluded that 70 to 95 percent
of the mass testing costs
are being reimbursed by medical insurance,
while the local governments pick up a fraction of the total cost.
Meanwhile,
official data shows that by the end of 2021,
the cumulative balance of the basic medical insurance fund,
which includes maternity insurance,
was at 3.6 billion yuan,
that's approximately 542 billion U.S. dollars.
The balance is mainly concentrated
in relatively wealthy provinces and regions
with larger populations.
The Health Literacy Bureau,
an information platform in China's medical and health field,
revealed in an article published May 26th
that there's a risk of exhausting the medical insurance funds
across the nation.
For Beijing and Shanghai,
the current medical insurance can fund the cost
of over 600 days of testing.
In contrast to what are considered
more densely populated provinces,
such as Shandong and Henan,
the current funds would run out
after about 70 days of testing.
Chinese state media, Yisai,
also confirmed local governments
had been using the public medical insurance
to pay for large-scale nucleic acid testing.
As an example,
the media outlet reported
both Guangdong province and Dalian city
covered testing costs
using the public medical insurance funds.
This indicates that local governments
spent the people's medical insurance funds
without any oversight and zero supervision.
Current affairs commentator and China expert Li Yanming
explained to the Epoch Times
that this happens because the CCP is a chaotic system.
The medical insurance fund
is not an administrative expenditure of a government,
but the local governments have the power
to use it for special purposes.
Since April this year,
several Chinese cities,
such as Shenzhen and Wuhan and Hangzhou,
have successively implemented
and normalized nucleic acid testing.
On May 9th,
the Chinese authorities called for the establishment
of a 15-minute sampling circle,
which translates into setting up
vast numbers of COVID sampling booths
so that every resident
is within about 15-minute walk
to their nearest testing site.
Analysts at Suzhou Securities
estimated the costly pandemic control measures
annual cost at 1.72 trillion yuan.
That's 258 billion US dollars
or 1.5% of China's GDP in 2021.
If it continues at the same pace in 2022,
it will surpass the CCP's 2022 defense budget
of 1.45 trillion yuan.
That's about 217 billion US dollars.
But those are conservative numbers
compared to Goldman Sachs
that had estimated testing 70%
of China's population every two days
to cost $370 billion
or 2.2% of China's 2021 GDP.
The nucleic acid testing market
has expanded rapidly
since the COVID-19 pandemic in 2020.
According to Tianyancha,
a Chinese business data and research platform,
in 2021 alone,
China added 437 businesses
dedicated to medical testing activities.
In February this year,
a leaked audio recording of Huang Wensheng,
a researcher at the Harvard-Yenching Institute,
circulated online.
The recording revealed
the Chinese regime's elite interest groups
had made a killing
off the pandemic control measures
thanks to vaccinations and testing.
According to the insider information,
one Chinese company alone
made over 670 billion yuan,
about 105 billion US dollars,
from nucleic acid testing at the time.
Commenting on Huang's recording,
Henry Wu Qialong, macroeconomist
and Taiwan AIA Capital Lead Economics researcher,
told the Epoch Times that in China,
since power is so tightly concentrated,
there is a lack of checks
and balances and supervision.
It is therefore very easy
for CCP elites to use power for personal gain.
These elites have turned
this large-scale public crisis
into an opportunity to line their pockets
with the public's funds.
